| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC8083 | NS11394 Featured | NS11394 possesses a functional efficacy selectivity profile of alpha(5) > alpha(3) > alpha(2) > alpha(1) at GABA(A) alpha subunit-containing receptors. |
|
| DC9734 | NS-1619 Featured | NS-1619 is a selective MaxiKα (large conductance calcium activated potassium channel) activator. |
|
| DC6910 | NS-1643 Featured | NS1643 is a potent human ether-a-go-go related gene (hERG) KV11.1 channel activator (EC50 = 10.5 μM). |
|
| DC7833 | NS309 Featured | NS309 is a positive modulator of small- and intermediate- conductance Ca2+-activated K+ channels (KCa2 and KCa3.1 channels); increases Ca2+ sensitivity. Displays no activity at BK channels. |
|
| DC8269 | NS6180 Featured | NS6180 is a novel inhibitor of the intermediate-conductance Ca2+-activated K+ channel (KCa3.1) |
|
| DC9856 | NS638 Featured | NS638 is a Ca(2+)-channel blocker. |
|
| DC7576 | NVP-AAM077 Featured | NVP-AAM077 is a potent antagonist for NMDA receptors. |
|
| DC11382 | NYX-2925 Featured | NYX-2925 is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory. |
|
| DC11096 | Olacaftor | Olacaftor (VX-440, VX440) is a next-generation CFTR corrector, showsthe potential to enhance the amount of CFTR protein at the cell’s surface and for treatment of cystic fibrosis.. |
|
| DC11267 | ONO-8590580 Featured | ONO-8590580 is a Novel GABAAα5 Negative Allosteric Modulator Enhances Long-Term Potentiation and Improves Cognitive Deficits in Preclinical Models. |
|
| DC11905 | Opiranserin Featured | Opiranserin (VVZ-149, VVZ-000149) is a potent, selective, mixed glycine GlyT2 transporter blocker (IC50= 0.86 uM), purine P2X3 receptor antagonist (IC50=0.87 uM) and serotonin 5-HT2A receptor antagonist (IC50=1.3 uM). |
|
| DC7262 | Optovin Featured | Optovin is a reversible photoactive TRPA1 activator. |
|
| DC10394 | Org-26576 | Org 26576 is a AMPA receptor positive allosteric modulator. |
|
| DC9001 | Oxcarbazepine | Oxcarbazepine inhibits the binding of [3H]BTX to sodium channels with IC50 of 160 μM and also inhibits the influx of 22Na+ into rat brain synaptosomes with IC50 about 100 μM. |
|
| DC10399 | PAC-14028 | PAC-14028 is a potent and selective transient receptor potential vanilloid type I (TRPV1) antagonist. |
|
| DC10292 | Pagoclone | Pagoclone is an active (+)-enantiomer of the racemate RP 59037. Pagoclone is a partial GABA(A) receptor agonist used for the treatment of panic and anxiety disorders. |
|
| DC9876 | Pantoprazole | Pantoprazole is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease. |
|
| DC9135 | Pantoprazole Sodium | Pantoprazole sodium salt(SKF96022; Protonix) is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease. |
|
| DC9098 | Paroxetine HCl Featured | Paroxetine hydrochloride hemihydrate is a antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). |
|
| DC7989 | PEPA Featured | PEPA is an allosteric modulator of AMPA receptors; binds to the GluA2o and GluA3o LBDs and can be utilized as an indicator of AMPA receptor heterogeneity. |
|
| DC7226 | Perampanel(E2007） Featured | Perampanel(E2007; ER 155055-90) is a selective noncompetitive AMPA-type glutamate receptor antagonist which has demonstrated anticonvulsant activity in experimental seizure models and antiepileptic activity in clinical trials. |
|
| DC10356 | PF 03716556 | PF 03716556 is a potent, and selective acid pump (H+,K+ ATPase) antagonist, with pIC50 value of 6.009. |
|
| DC10529 | PF 05089771 Featured | PF 05089771 is a Nav1.7 channel blocker extracted from patent WO/2010/079443 A1, compound example 788, has an IC50 of 8.6 nM. |
|
| DC10038 | PF-01247324 Featured | PF-01247324 is an orally bioavailable, selective and potent NaV1.8 channel blocker that inhibits that exhibits analgesic efficacy in rodent behavioral models of pain. |
|
| DC3108 | PF-04971729 (Ertugliflozin) Featured | PF-04971729 is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2, is currently in phase 2 trials for the treatment of diabetes mellitus. |
|
| DC12334 | PF-05241328 | PF-05241328 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channels (Nav1.7), with an IC50 of 31 nM. |
|
| DC11966 | PF-06678419 | PF-06678419 (PF06678419) is a potent, selective inhibitor of the Na+/citrate transporter NaCT (SLC13A5) that shows inhibition of citrate uptake in the HEKNaCT cells with IC50 of 0.44 uM. |
|
| DC10834 | PF-06869206 Featured | PF-06869206 is an Orally Bioavailable Selective Inhibitors of the Sodium-Phosphate Cotransporter NaPi2a (SLC34A1). |
|
| DC11188 | PF-4778574 | PF-4778574 (PF4778574) is a brain penetrant, positive allosteric modulator (potentiator) of AMPA receptor with Ki of 85 nM, increases S-AMPA-evoked responses in rat primary cortical neurons with EC50 of 45-919 nM. |
|
| DC9024 | Phenytoin sodium | Phenytoin sodium is an inactive voltage-gated sodium channel stabilizer. |
|
